Previous studies have indicated that histone deacetylase inhibitors (HDACi) can reduce tumor formation and induce intrinsic apoptosis in breast cancer cells by targeting HDAC5, which relies on the activation of the intrinsic apoptosis pathway involving caspase 9/3 signaling [39]. The gene discussed is CASP9; the disease is breast carcinoma.